« Previous article
Point-of-Care Rapid ...

17th May 2021  Product update: rapidvirology staff writer

CRISPR Licensing Cuts To The Chase in Defeating COVID-19 Around the World

The 221b Foundation, the nonprofit organization established by Sherlock Biosciences, has now granted several organizations a license to develop and distribute their own CRISPR-based COVID-19 tests using SHERLOCK technology. 

So far, licensed organizations include Cooper Pharma, Rokline Health Concepts, United PPE, and LogicInk.

By providing its CRISPR technology, called SHERLOCK, through The 221b Foundation, Sherlock is facilitating pathways for the development and delivery of rapid, accurate, and automatable solutions to directly benefit patients and the fight against the global COVID-19 pandemic.

The SHERLOCK diagnostic platform can achieve single-molecule detection of nucleic acid targets; its name stands for Specific High Sensitivity Enzymatic Reporter unLOCKing. SHERLOCK utilizes CRISPR activity for “smart amplicon detection” and can be adapted for use with existing diagnostic instruments, improving time to result due to its significant multiplexing capacity. When a specific sequence of DNA or RNA is present, a CRISPR enzyme is activated and, much like a pair of scissors, starts cutting nearby genetic material, releasing a fluorescent signal that indicates a positive result.

In May 2020, Sherlock received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock™ CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology.

Click here to download the whitepaper from Sherlock Biosciences on its CRISPR SARS-CoV-2 Test.



Date Published: 17th May 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.

View full company details

Related news